An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Skin Ulcer Venous Stasis Chronic
- Sponsor
- RHEACELL GmbH & Co. KG
- Enrollment
- 31
- Locations
- 9
- Primary Endpoint
- Percentage of wound size reduction
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the medicinal product to be studied after two applications on the wound surface in patients with Chronic Venous Ulcers.
Detailed Description
This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (MSCs) on wound healing in patients with chronic venous ulcer (CVU). Allogeneic MSCs will be isolated ex vivo and will be expanded in vitro. The IMP incorporating the ABCB5-positive MSCs will then be applied on the wound surface of CVU under local anesthesia (on Day 0 and Week 6.1). Wound measurements from Visit (V) 2 and V9 will be used to determine the cell amount for the IMP treatments on V3 and V10, respectively. Patients are followed up for efficacy for 3 months which allows to distinguish actual wound healing from transient wound coverage. The wound healing process will be documented by standardized photography. The wound size evaluation will start on the day of the first change of wound dressing. The quality of the wound healing process will be assessed on the basis of formation of granulation tissue, epithelialization and wound exudation. Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires. To assess long-term safety of allo-APZ2-CVU three follow-up visits at Months 6, 9 and 12 after the first IMP applications are included.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female patients aged 35 to 85 years;
- •Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant ulcer that shows no improvement within 3 months despite of optimal phlebological therapies or is not healed within 12 months) diagnosed by doppler ultrasonography (DUS), ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;
- •Wound size of target ulcer between 1.5 and 100 cm2 measured by a standardized photography at the screening visits (Visit 1 and Visit 2);
- •Wound location below knee;
- •If patients are suffering from 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);
- •Body mass index (BMI) between 20 and 45 kg/m²;
- •Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
- •Women of childbearing potential must have a negative blood pregnancy test at Visit 1
- •Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.
Exclusion Criteria
- •Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
- •Current use of systemic steroid medication above Cushing threshold dose (\>7.5 mg/d prednisone or equivalent);
- •Diabetes mellitus that has to be evaluated by blood test (Haemoglobin A1c \[HbA1c\] \>7.5%);
- •Peripheral Artery Disease (PAD) including claudication with need of treatment;
- •Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
- •Unable to tolerate leg ulcer compression bandage;
- •Infection of the target ulcer requiring treatment as judged clinically;
- •Any chronic dermatological disorders diagnosed at the investigator's discretion;
- •Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;
- •Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
Outcomes
Primary Outcomes
Percentage of wound size reduction
Time Frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing
Percentage of wound size reduction at Week 12, or last available post-baseline measurement of Weeks 6, 8 or 10 if the Week 12 measurement is missing (last observation carried forward \[LOCF\]).
Assessment of adverse event (AE) occurrence
Time Frame: Up to 12 months
All AEs occurring during the clinical trial will be registered, documented and evaluated.
Secondary Outcomes
- Percentage of wound size reduction(Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12 (without LOCF);)
- Absolute wound size reduction(Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12)
- Proportion of patients achieving complete wound closure(Weeks 2, 3, 4, 6, 8, 10, 12, and at any time point)
- Time to first complete wound closure(A priori specification not possible; between baseline and week 12 post baseline)
- Physical examination and vital signs at Week 6.1 and Week 12(Week 6.1 and Week 12)
- Epithelialization(Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12)
- Assessment of dermatology-specific quality of life based on the Dermatology Life Quality Index (DLQI) questionnaire(Day 0 and Weeks 4, 8 and 12)
- Proportion of patients achieving 30% wound closure(Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, 12, and at any time point)
- Time to first 30% wound closure(A priori specification not possible; between baseline and week 12 post baseline)
- Assessment of further wound healing parameters: formation of granulation tissue and wound exudation(Visit 3 and Visit 10 before IMP application, Days 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.2, 8, 10, and 12)
- Pain assessment as per numerical rating scale (NRS)(Days 0, 1 to 3 and 8, Weeks 2, 3, 4, 6, 6.1, 6.2, 8, 10, and 12)
- Assessment of quality of life (QoL) using the short form 36 (SF-36) questionnaire(Day 0 and Weeks 4, 8 and 12)